Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous human Schwann cells in chronic spinal cord injury
NCT02354625Phase 1Completed
- Start
- Jan 2015
- Primary completion
- Aug 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous human Schwann cells in spinal cord injury (SCI). Primary endpoints: International Standards of Neurological Classification of Spinal Cord Injury at 6 months, Magnetic Resonance Imaging of spinal cord at 6 months and 4 more. Started Jan 2015; status: completed.
02
Drugs
autologous human Schwann cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02354625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354625.